Retatrutide research: Phase 1 through Phase 2 findings and what is currently being studied

The short version

Retatrutide is an investigational drug — meaning it has not been approved anywhere — that is being studied in large clinical trials for obesity and type 2 diabetes. It targets three hormone receptors simultaneously, which appears to produce larger weight loss than drugs that target only one or two. The published clinical evidence spans a first-in-human safety study (Phase 1b), two Phase 2 trials with roughly 600 participants total, a liver-fat substudy, and a wave of recent preclinical work on cancer, fat-tissue biology, and structural pharmacology. This page summarizes those studies with their primary findings cited. All efficacy figures come from trial populations, not from general use — retatrutide is not yet an approved medicine.

Phase 1b: first-in-human safety and pharmacokinetics

The first clinical study of retatrutide enrolled 72 adults with type 2 diabetes (HbA1c 7.0–10.5%) in a multicentre, double-blind, placebo-controlled, multiple-ascending-dose design. Participants received once-weekly subcutaneous injections at doses of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg over 12 weeks ^[4].

Key pharmacokinetic finding: retatrutide has an approximately 6-day half-life — the time for blood concentration to fall by half — a parameter that directly supports once-weekly dosing. (For reference, once-daily dosing would indicate a half-life of roughly 12–24 hours; once-weekly dosing requires a half-life on the order of multiple days.)

Efficacy signal: placebo-adjusted body-weight reduction at the highest dose group was −8.96 kg (90% CI −11.16 to −6.75) over 12 weeks. Daily glucose fell by −2.8 mmol/L at 3 mg. Treatment-emergent adverse events (TEAEs — any untoward health event occurring during treatment) occurred in 63% of participants, mostly GI in character; the safety profile was characterized as acceptable by the investigators ^[4].

This Phase 1b established the tolerability window and PK (pharmacokinetics — the drug's behavior in the body over time) that informed the subsequent Phase 2 dose range.

Phase 2 obesity trial

Jastreboff et al. (N Engl J Med, 2023) enrolled 338 adults with BMI ≥30 or ≥27 with a weight-related comorbidity; 51.8% were men. Participants received once-weekly subcutaneous injections of 1, 4, 8, or 12 mg or placebo for 48 weeks ^[1].

Primary efficacy endpoint: mean percent body-weight change at 48 weeks.

• 12 mg: −24.2% vs −2.1% placebo
• 8 mg: −22.8%
• 4 mg: −17.3%
• 1 mg: −8.7%

All active-dose groups significantly outperformed placebo. The 12 mg result — a 24-percentage-point placebo-adjusted loss — exceeded outcomes reported in pivotal trials of approved GLP-1 receptor agonists at comparable duration ^[1].

Safety summary: GI adverse events (nausea, diarrhea, vomiting, constipation) were dose-related and mostly mild-to-moderate. Nausea affected up to 45% of the 12 mg group. A dose-dependent increase in resting heart rate was observed, peaking at approximately week 24. Discontinuation rate at 12 mg: 18%, primarily GI-driven.

A commentary in the Journal of Pharmacy Technology (Derawi et al., 2024) summarized the Phase 1-to-Phase 2 trajectory, noting that phase 1 established the dosing escalation feasibility and tolerability profile that enabled the 24% weight loss and nearly 20 cm waist circumference reduction documented in Phase 2 ^[10].

Phase 2 type 2 diabetes trial

Rosenstock et al. (Lancet, 2023) enrolled 281 adults with type 2 diabetes in a randomized, double-blind, placebo- and active-controlled, parallel-group design. The stepwise dose escalation ran from 0.5 to 12 mg once weekly ^[2].

Glycemic endpoint at 24 weeks (12 mg vs placebo): HbA1c −2.02% vs −0.01%. HbA1c (glycated hemoglobin) is a blood-test marker reflecting average blood glucose over approximately three months; a 2% reduction represents a clinically substantial correction.

Weight endpoint at 36 weeks (12 mg vs placebo): −16.94% vs −3.00%.

Safety: GI adverse events in 35% of participants; no severe hypoglycemia; no deaths. This trial provides the basis for claims about retatrutide's potential in type 2 diabetes management ^[2], though the compound remains unapproved and all findings are from clinical-trial conditions only.

Retatrutide vs tirzepatide: No head-to-head human trial has been published. A 2026 study in MC4R knockout mice — a model of genetic obesity in which the melanocortin-4 receptor, a key energy-regulation pathway, is non-functional — compared the three GLP-1-class compounds: tirzepatide led with 31.6% body-weight reduction, followed by retatrutide at 24.1% and semaglutide at 19.7%, with all three agents improving insulin sensitivity, HOMA-IR (a measure of insulin resistance), cholesterol, and lipid markers ^[12]. This preclinical comparison cannot be directly translated to human efficacy rankings, which require head-to-head trials.

A dedicated active-comparator Phase 3 trial of retatrutide versus tirzepatide is among the TRIUMPH program studies; results are pending.

MASLD substudy: liver-fat reduction

Sanyal et al. (Nature Medicine, 2024) reported a prospectively planned substudy of 98 participants from the Phase 2 obesity trial who had MASLD — at least 10% liver fat by MRI-PDFF (magnetic resonance imaging proton density fat fraction, a non-invasive method for measuring liver fat content) and no type 2 diabetes ^[5].

Liver-fat change at 24 weeks (relative):

• 1 mg: −42.9%
• 4 mg: −57.0%
• 8 mg: −81.4%
• 12 mg: −82.4%
• Placebo: +0.3%

At 12 mg, 86% of participants reached normal liver-fat content (<5%). Reductions sustained to week 48, where the 12 mg group showed −86.0%. These findings are notable because MASLD affects the majority of people with obesity and has limited approved pharmacotherapy; no dedicated MASLD approval yet exists for any GLP-1-class compound. These figures come from a Phase 2 substudy — confirmation at Phase 3 scale is required.

Structural biology and preclinical pharmacology

Li et al. (Cell Discovery, 2024) resolved cryo-EM structures of retatrutide in complex with all three receptors — GLP-1R, GIPR, and GCGR — at resolutions of 2.68, 3.26, and 2.84 Å (ångströms — unit of atomic-scale distance) respectively ^[3]. These structures confirm simultaneous triple-receptor engagement at atomic resolution.

Relative potency versus endogenous hormones: 8.9× at GIPR, 0.3× at GCGR, 0.4× at GLP-1R. A structural feature of note: extracellular loop 1 (ECL1 — a segment of the receptor that projects outward and participates in ligand docking) adopts a rigid alpha-helix when retatrutide engages GLP-1R and GCGR, but a flexible loop when engaging GIPR — a receptor-specific structural adaptation that contributes to the differential potency profile ^[3].

A 2025 preclinical study found that retatrutide produced a 14-fold reduction in pancreatic tumor volume and a 17-fold reduction in lung tumor volume compared to vehicle in mouse tumor models, with anti-tumor effects persisting despite weight regain ^[11]. A 2026 multi-omic profiling study found that retatrutide reprogrammed white adipose tissue (the primary fat-storage tissue) at the transcriptomic and metabolomic levels: suppressed lipogenesis (fat production), enhanced fatty-acid oxidation and mitochondrial function, downregulated inflammatory and fibrotic pathways, and elevated anti-inflammatory 15-HETE ^[13].

These preclinical results extend the pharmacological profile of retatrutide beyond weight loss and glycemia. Clinical translation of the anti-tumor and adipose-remodeling findings remains to be demonstrated in human trials.

Phase 3 TRIUMPH program and ongoing trials

Eli Lilly's TRIUMPH (Triple Hormone Receptor Agonist for Metabolic Progress and Health) program encompasses multiple Phase 3 studies, including trials in obesity (TRIUMPH-1, -2, -3), type 2 diabetes, cardiovascular outcomes (NCT06383390), chronic kidney disease (TRANSCEND-CKD: NCT05929066, NCT05931367), and an active-comparator study versus tirzepatide. None of these trials have reported results as of 2026.

Until Phase 3 data are available and regulatory submissions reviewed, retatrutide cannot be characterized as a proven treatment for any indication. This site will update its literature summaries as peer-reviewed data are published.